Thiazolidinediones and cardiovascular outcomes in type 2 diabetes

Heart

Volumn 95, Issue 1, 2009, Pages 1-2

  Singh, Sonal ^a   Furberg, Curt D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLICLAZIDE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; NITRATE; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SPIRONOLACTONE; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE MARKER; DISEASE SEVERITY; EDITORIAL; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 58349095981     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.155507     Document Type: Editorial

References (39)

1. Rosamond W, Flegal K, Friday G, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics- 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171.
2. Bethel MA, Sloan FA, Belsky D, et al. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med 2007; 167:921-7.
3. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115:114-26.
4. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub study. Lancet 2000; 355:253-9.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
6. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-59.
7. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-72.
8. Gever J. ADA: VA diabetes trial appears to vindicate rosiglitazone (Avandia) safety. Presented at the American Diabetes Association Scientific Sessions. San Francisco 2008. Available at http://www.medpagetoday.com/MeetingCoverage/ADA/tb/9749 (accessed 11 August 2008).
9. European Agency for the Evaluation of Medicinal Products (EMEA). EPARS for authorised medicinal products for human use. Avandia. London, England, 2007. Available at http://www.emea.europa. eu/humandocs/Humans/EPAR/ avandia/avandia.htm (accessed 11 August 2008).
10. Qayyum R, Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens (Greenwich) 2006; 8:19-28.
11. Qayyum R, Adomaityte J. Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels. Am J Cardiol 2006; 97:655-8.
12. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164:2097-104.
13. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-89.
14. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27:256-63.
15. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007; 30:2148-53.
16. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096-105.
17. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370:1129-36.
18. Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008; 29:12-20.
19. Zhang H, Zhang A, Kohan DE, et al. Collecting ductspecific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 2005; 102:9406-11.
20. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 56:2457-71.
21. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a metaanalysis. JAMA 2007; 298:1189-95.
22. U.S. Food and Drug Administration. FDA briefing document. Division of Metabolism and Endocrine Products and Office of Surveillance and Epidemiology. Joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee July 30, 2007. U.S. Food and Drug Administration, 2007. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-02-fda-backgrounder. pdf. (accessed 19 August 2008).
23. GlaxoSmithKline. GlaxoSmithKline clinical trial register: study No. ZM2005/00181/01, Avandia cardiovascular event modeling project, and study No. HM2006/00497/00/WEUSRTP866, Coronary heart disease outcomes in patients receiving antidiabetic agents. Available at http://ctr.gsk.co.uk/ Summary/Rosiglitazone/III-CVmodeling.pdf (accessed 19 August 2008).
24. Lipscombe LL, Gomes T, LevesqueLE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298:2634-43.
25. Wang CP, Haffner S, Defronzo R, et al. Differential rosiglitazone effects on cardiovascular disease in VA type 2 diabetes patients. Abstract Number 604-P 2008. American Diabetes Association, San-Francisco. Available at http://scientificsessions.diabetes.org/index.cfm?fuseaction = Locator.PreviewAbstract &popup = yes&NoLayout = Yes&AbstractID = 3929 (accessed 11 August 2008).
26. Sapunar J, Muñoz S, Jiménez M, et al. Effect of baseline sample characteristics, comparator drug, cointerventions and rosiglitazone doses on the risk of myocardial infarction: multivariable lineal regression analysis. Abstract OC3.9 May 5 at the 10th European Congress of Endocrinology (ECE). Berlin. Available at http://www.pslgroup.com/news/content. nsf/medicalnews/852571020057CCF685257443005F1622? OpenDocument&id = &count = 10 (accessed 11 August 2008).
27. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298:1180-8.
28. Mannucci E, Monami M, Lamanna C, et al. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008 May 26. [Epub ahead of print]. doi 10.1111/j.1463-1326.2008.00892.x
29. Deeg MA, Buse JB, Goldberg RB, et al. on behalf of the GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007; 30:2458-64.
30. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28:1547-54.
31. Orasanu G, Ziouzenkova O, Devchand PR, et al. The peroxisome proliferator-activated receptor-[gamma] agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-[alpha]- dependent manner in vitro and in vivo in mice, J Am Coll Cardiol 2008 July 2. [Epub ahead of print]. doi:10.1016/j.jacc.2008.04.055
32. McGuire DK, Inzucchi SE. New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications. Circulation 2008; 117:440-9.
33. Hsiao A, Worrall DS, Olefsky JM, et al. Variancemodeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics 2004; 20:3108-27.
34. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-43.
35. Takeda Pharmaceuticals. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCI) tablets for type 2 diabetes mellitus. Available at http://www.fda.gov/medwaTCH/safety/2007/Actosmar0807.pdf (accessed 11 August 2008).
36. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168:820-5.
37. Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina 2006; 26:562-70.
38. Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee. July 1-2, 2008. Available at http://www.fda.gov/ohrms/ dockets/ac/08/briefing/2008-4368b1-00-FDA-index.htm (accessed 11 August 2008).
39. Nathan DM, Buse JB, Davidson MB, et al. Consensus Statement update. Management of hyperglycemia in type 2 diabetes mellitus: a consensus update regarding the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetolgia 2008; 31:173-5.